Your browser doesn't support javascript.
loading
Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma.
Costa, Luciano J; Giri, Smith; Bal, Susan; Ravi, Gayathri; Godby, Kelly N.
Affiliation
  • Costa LJ; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Giri S; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Bal S; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Ravi G; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Godby KN; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Br J Haematol ; 200(6): 824-827, 2023 03.
Article in En | MEDLINE | ID: mdl-36649972
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms, Plasma Cell / Multiple Myeloma Limits: Humans Language: En Journal: Br J Haematol Year: 2023 Document type: Article Affiliation country: United States Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms, Plasma Cell / Multiple Myeloma Limits: Humans Language: En Journal: Br J Haematol Year: 2023 Document type: Article Affiliation country: United States Country of publication: United kingdom